Data demonstrate dose dependent survival advantage with AUTX-703 in primary patient-derived orthotopic AML model ...
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment ...
When combined with venetoclax and azacitidine (standard-of-care treatments for AML), STX-0712 improved therapeutic efficacy in 60% of patient samples by differential targeting both CCR2-positive ...
WEST CHESTER, PA, USA I 09, 2024 I Molecular Targeting Technologies, Inc. (MTTI) published preclinical study results for their proprietary ...
Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy ...
SUZHOU, China I 8, 2024 I CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and ...
SHANGHAI, China I 04, 2024 I Shanghai Henlius Biotech, Inc. (2696.HK) announced that the new drug application (NDA) has been accepted by the National ...
SHANGHAI, China I 4, 2024 I Shanghai Henlius Biotech, Inc. (2696.HK) announced that the investigational new drug (IND) application for a phase 1b/2 ...
Following on from a period of exclusive evaluation announced in June 2024, Genmab has exercised its option to license an anti-glycan monoclonal antibody ...
Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts ...
SOUTH SAN FRANCISCO, CA, USA I 05, 2024 I Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical ...
STOCKHOLM, Sweden I 5, 2024 I BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab ...